ABSTRACT Ten patients with severe dyspnoea and chronic airflow obstruction entered a randomised double-blind crossover trial comparing the effect of carbimazole 80 mg daily for two months with that of placebo. Assessment of thyroid function, lung function, and exercise tolerance was performed monthly. The mean free thyroxine index after two months of carbimazole was significantly lower at 64 1 (± 10.5, SEM) than the 89-1 (± 3*8) while on placebo. Serum tri-iodothyronine was reduced and thyroid stimulating hormone raised while on the active drug. There was no significant difference in the 12-minute walking distance (TMD), the rating of perceived exertion during the TMD, the oxygen cost score, the dyspnoea grade, the resting arterialised capillary blood gas tensions or the resting minute ventilation. During a progressive exercise test to exhaustion on a cycle ergometer, there was no significant difference in the minute ventilation, heart rate, blood gas tensions at exhaustion, or the total work done. There were no symptoms or signs of hypothyroidism. Lung function (FEV1, FVC, TLC, Kco) was unchanged. Thus a 28 % reduction in the free thyroxine index produced no symptomatic or objective benefit in exercise tolerance in patients with severe airflow obstruction. These results provide no support for the use of carbimazole in chronic airflow obstruction.
The induction of hypothyroidism with radioiodine has been used in attempts to alleviate the dyspnoea of chronic airflow obstruction.1-5 These studies claimed benefit but were uncontrolled and tended to produce the clinical features of myxoedema.
In a patient with emphysema and coincidental myxoedema, thyroxine replacement was associated with a reduction in exercise tolerance and an increase in ventilation. 6 Changes in ventilation are probably the mechanism by which anti-thyroid treatment improves dyspnoea. Patients with thyrotoxicosis have a high minute ventilation and patients with myxoedema a low minute ventilation. These changes are present both at rest and on exercise, and are a reflection of changes in metabolic rate, ventilatory drive, and muscular weakness.7-14 It might thus be possible to reduce ventilation and improve exercise tolerance by a modest reduction in thyroid function.
We have therefore conducted a double-blind placebo controlled trial of carbimazole in patients with chronic airflow obstruction in an attempt to improve exercise tolerance. We reduced thyroid function but not to a degree that would produce hypothyroid symptoms.
Methods
Ten patients, mean age 60 years (SD = 11 years), whose major symptom was breathlessness caused by irreversible chronic airflow obstruction (FEV1 < 11) were studied. Patients with evidence of other lung disease, thyroid disease, serious disease of other organ systems, or a Paco2 above Mean values (± SE) for exercise testing on consecutive months of the trial, regardless of whether carbimazole or placebo were being taken, are shown (figure). In the progressive exercise test, at exhaustion total work done, heart rate, and minute ventilation fell progressively (p < 0-0l). In contrast the 12-minute distance remained steady but the rating of perceived exertion gradually increased. There were no significant changes in lung function or blood gas tensions. 
Discussion
This study demonstrated that a 280% reduction in the mean FTI produced no symptomatic or objective change in exercise tolerance in patients with severe chronic airflow obstruction. There was no benefit in the four patients whose FTI fell into the hypothyroid range.
The group of patients studied may not represent a cross-section of chronic airflow obstruction as we excluded hypercapnic subjects because ventilatory drive is reduced in hypothyroidism"1314 and such a reduction could be detrimental to patients with hypercapnic respiratory failure. Also all the patients had radiological evidence of emphysema (overinflation). However, patients with emphysema hyperventilate during exercise as compared with chronic bronchitics matched for a similar degree of airflow obstruction20 and might, therefore, be expected to benefit more from a lower ventilatory rate.
The 
